Clinical experience with COP-1 in multiple sclerosis.

@article{Bornstein1988ClinicalEW,
  title={Clinical experience with COP-1 in multiple sclerosis.},
  author={Murray B. Bornstein and Aaron Miller and Sharon Slagle and Michael Weitzman and Howard J Crystal and Eva Drexler and Marshall Keilson and Aaron R Merriam and Sylvia Wassertheil-Smoller and V L Spada},
  journal={Neurology},
  year={1988},
  volume={38 7 Suppl 2},
  pages={66-9}
}
COP-1 is one of a series of polypeptide preparations developed to stimulate myelin basic protein (MBP), a natural component of the myelin sheath. MBP in Freund's complete adjuvant induces experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). In saline, MBP suppresses EAE. This is the rationale for the use of COP-1 in MS.